Professor | Changtao Jiang | Asia Growth Partners

Upload Avatar (500 x 500)

Name

Changtao Jiang

Contact Information

jiangchangtao@bjmu.edu.cn

Language ability

Chinese, English

Province

Beijing

University/Lab Affiliation and Title	Peking University
Faculty	Basic Medical Sciences
Academic Background & Achievements	Recipient of the National Science Fund for Distinguished Young Scholars Recipient of the Science Exploration Award
Work Experience	Professor at Peking University, School of Basic Medical Sciences Vice Dean at Peking University, School of Basic Medical Sciences
Awards	Science Exploration Award China Youth Science and Technology Award Shulan Medical Youth Award CADA Young Scientist Award Mao Yisheng Beijing Youth Science and Technology Award

University/Lab Affiliation and Title

Peking University

Faculty

Basic Medical Sciences

Academic Background & Achievements

Work Experience

Awards

Areas of Focus	Gut microbiota and metabolic disease pathogenesis
Publications	Microbial-host-isozyme analyses reveal microbial DPP4 as a potential antidiabetic target, Jiang CT et al., 2023 Gut bacteria alleviate smoking-related NASH by degrading gut nicotine, Jiang CT et al., 2022 Intestinal hypoxia-inducible factor 2α regulates lactate levels to shape the gut microbiome and alter thermogenesis, Jiang CT et al., 2021 Gut microbiota and intestinal FXR mediate the clinical benefits of metformin, Jiang CT et al., 2018 Adipocyte hypoxia-inducible factor 2α suppresses atherosclerosis by promoting adipose ceramide catabolism, Jiang CT et al., 2019 Suppressing the intestinal farnesoid X receptor/sphingomyelin phosphodiesterase 3 axis decreases atherosclerosis, Jiang CT et al., 2021 Hyocholic acid species improve glucose homeostasis through a distinct TGR5 and FXR signaling mechanism, Jiang CT et al., 2021 Gut microbiota-bile acid-interleukin-22 axis orchestrates polycystic ovary syndrome, Jiang CT et al., 2019 Activation of intestinal hypoxia-inducible factor 2α during obesity contributes to hepatic steatosis, Jiang CT et al., 2017 Macrophage HIF-2α suppresses NLRP3 inflammasome activation and alleviates insulin resistance, Jiang CT et al., 2021

Areas of Focus

Gut microbiota and metabolic disease pathogenesis

Publications

Microbial-host-isozyme analyses reveal microbial DPP4 as a potential antidiabetic target, Jiang CT et al., 2023
Gut bacteria alleviate smoking-related NASH by degrading gut nicotine, Jiang CT et al., 2022
Intestinal hypoxia-inducible factor 2α regulates lactate levels to shape the gut microbiome and alter thermogenesis, Jiang CT et al., 2021
Gut microbiota and intestinal FXR mediate the clinical benefits of metformin, Jiang CT et al., 2018
Adipocyte hypoxia-inducible factor 2α suppresses atherosclerosis by promoting adipose ceramide catabolism, Jiang CT et al., 2019
Suppressing the intestinal farnesoid X receptor/sphingomyelin phosphodiesterase 3 axis decreases atherosclerosis, Jiang CT et al., 2021
Hyocholic acid species improve glucose homeostasis through a distinct TGR5 and FXR signaling mechanism, Jiang CT et al., 2021
Gut microbiota-bile acid-interleukin-22 axis orchestrates polycystic ovary syndrome, Jiang CT et al., 2019
Activation of intestinal hypoxia-inducible factor 2α during obesity contributes to hepatic steatosis, Jiang CT et al., 2017
Macrophage HIF-2α suppresses NLRP3 inflammasome activation and alleviates insulin resistance, Jiang CT et al., 2021

Gut Microbiota Metabolic Disease Pathogenesis Bile Acids Nicotine Ceramides Isozymes Dpp4 Intestinal Targets Therapeutics

Duan Ma - Fudan University

Yuxiang Wang - Fudan University

Tang Yong - Chongqing Medical University

View All

Personal Information